Advertisement

Mitochondrial Depletion Syndromes

  • Sumit Parikh
  • Rita Horvath
Chapter

Abstract

Mitochondrial DNA (mtDNA) depletion syndromes are characterized by a reduced number of mtDNA compared to nuclear DNA in affected tissues. The molecular cause of these clinically very heterogeneous diseases is autosomal recessive mutations in at least 15 nuclear genes involved in nuclear-mitochondrial inter-genomic signaling pathways. The phenotypes for these disorders can be quite varied from isolated ophthalmoplegia to multi-system disease. Almost all of the mtDNA depletion disorders can present with isolated chronic progressive ophthalmoplegia (CPEO). More extensive involvement leads to one of several various phenotypes with a primary myopathic, cardiomyopathic, encephalomyopathic, hepatocerebral, or neurogastrointestinal presentation. These categorizations, while imperfect, provide some structure around which to organize the diverse presentations of mtDNA depletion diseases. Most of these disorders have additional less common presentations, and these phenotypes are discussed within the context of the above categories.

In this chapter we discuss the clinical presentations and the latest updates in the state-of-the-art diagnosis and treatment of mtDNA maintenance diseases, including the compilation of new genes, new findings on why and how these dysfunctional genes and related proteins lead to the associated severe symptoms, as well as preclinical and clinical evidence on the plausibility of new treatments.

Keywords

Mitochondrial DNA depletion disorders 

References

  1. 1.
    Nogueira C, Almeida LS, Nesti C, Pezzini I, Videira A, Vilarinho L, et al. Syndromes associated with mitochondrial DNA depletion. Ital J Pediatr. 2014;40:34.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Viscomi C, Zeviani M. MtDNA-maintenance defects: syndromes and genes. J Inherit Metab Dis. 2017;40(4):587–99.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Fasullo M, Endres L. Nucleotide salvage deficiencies, DNA damage and neurodegeneration. Int J Mol Sci. 2015;16(5):9431–49.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Johansson M, Karlsson A. Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2. J Biol Chem. 1997;272(13):8454–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet. 2001;29(3):342–4.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Garone C, Taylor RW, Nascimento A, Poulton J, Fratter C, Domínguez-González C, Evans JC, Loos M, Isohanni P, Suomalainen A, Ram D, Hughes MI, McFarland R, Barca E, Lopez Gomez C, Jayawant S, Thomas ND, Manzur AY, Kleinsteuber K, Martin MA, Kerr T, Gorman GS, Sommerville EW, Chinnery PF, Hofer M, Karch C, Ralph J, Cámara Y, Madruga-Garrido M, Domínguez-Carral J, Ortez C, Emperador S, Montoya J, Chakrapani A, Kriger JF, Schoenaker R, Levin B, Thompson JLP, Long Y, Rahman S, Donati MA, DiMauro S, Hirano M. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet. 2018;55(8):515–21.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Pons R, Andreetta F, Wang CH, Vu TH, Bonilla E, DiMauro S, et al. Mitochondrial myopathy simulating spinal muscular atrophy. Pediatr Neurol. 1996;15(2):153–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Mancuso M, Salviati L, Sacconi S, Otaegui D, Camano P, Marina A, et al. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology. 2002;59(8):1197–202.PubMedCrossRefGoogle Scholar
  9. 9.
    Lesko N, Naess K, Wibom R, Solaroli N, Nennesmo I, von Dobeln U, et al. Two novel mutations in thymidine kinase-2 cause early onset fatal encephalomyopathy and severe mtDNA depletion. Neuromuscul Disord. 2010;20(3):198–203.PubMedCrossRefGoogle Scholar
  10. 10.
    Termglinchan T, Hisamatsu S, Ohmori J, Suzumura H, Sumitomo N, Imataka G, et al. Novel TK2 mutations as a cause of delayed muscle maturation in mtDNA depletion syndrome. Neurol Genet. 2016;2(5):e95.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Marti R, Nascimento A, Colomer J, Lara MC, Lopez-Gallardo E, Ruiz-Pesini E, et al. Hearing loss in a patient with the myopathic form of mitochondrial DNA depletion syndrome and a novel mutation in the TK2 gene. Pediatr Res. 2010;68(2):151–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhang S, Li FY, Bass HN, Pursley A, Schmitt ES, Brown BL, et al. Application of oligonucleotide array CGH to the simultaneous detection of a deletion in the nuclear TK2 gene and mtDNA depletion. Mol Genet Metab. 2010;99(1):53–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Paramasivam A, Meena AK, Pedaparthi L, Jyothi V, Uppin MS, Jabeen SA, et al. Novel mutation in C10orf2 associated with multiple mtDNA deletions, chronic progressive external ophthalmoplegia and premature aging. Mitochondrion. 2016;26:81–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Chanprasert S, Wong LJC, Wang J, Scaglia F. TK2-related mitochondrial DNA depletion syndrome, myopathic form. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Mefford HC, et al., editors. GeneReviews(R). Seattle, WA: University of Washington, Seattle; 1993. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.Google Scholar
  15. 15.
    Garone C, Garcia-Diaz B, Emmanuele V, Lopez LC, Tadesse S, Akman HO, et al. Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med. 2014;6(8):1016–27.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, Juanola-Falgarona M, Barca E, Garcia-Diaz B, et al. Deoxycytidine and deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol. 2017;81(5):641–52.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Kornblum C, Nicholls TJ, Haack TB, Scholer S, Peeva V, Danhauser K, et al. Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease. Nat Genet. 2013;45(2):214–9.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Hebbar M, Girisha KM, Srivastava A, Bielas S, Shukla A. Homozygous c.359del variant in MGME1 is associated with early onset cerebellar ataxia. Eur J Med Genet. 2017;60(10):533–5.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Waggoner DW, Johnson LB, Mann PC, Morris V, Guastella J, Bajjalieh SM. MuLK, a eukaryotic multi-substrate lipid kinase. J Biol Chem. 2004;279(37):38228–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol. 2005;169(5):801–11.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Mayr JA, Haack TB, Graf E, Zimmermann FA, Wieland T, Haberberger B, et al. Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome. Am J Hum Genet. 2012;90(2):314–20.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Sengers RC, Trijbels JM, Willems JL, Daniels O, Stadhouders AM. Congenital cataract and mitochondrial myopathy of skeletal and heart muscle associated with lactic acidosis after exercise. J Pediatr. 1975;86(6):873–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med. 2012;4(118):118ra10.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Parikh S, Karaa A, Goldstein A, Ng YS, Gorman G, Feigenbaum A, et al. Solid organ transplantation in primary mitochondrial disease: proceed with caution. Mol Genet Metab. 2016;118(3):178–84.PubMedCrossRefGoogle Scholar
  25. 25.
    Neckelmann N, Li K, Wade RP, Shuster R, Wallace DC. cDNA sequence of a human skeletal muscle ADP/ATP translocator: lack of a leader peptide, divergence from a fibroblast translocator cDNA, and coevolution with mitochondrial DNA genes. Proc Natl Acad Sci U S A. 1987;84(21):7580–4.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Li K, Warner CK, Hodge JA, Minoshima S, Kudoh J, Fukuyama R, et al. A human muscle adenine nucleotide translocator gene has four exons, is located on chromosome 4, and is differentially expressed. J Biol Chem. 1989;264(24):13998–4004.PubMedGoogle Scholar
  27. 27.
    Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000;289(5480):782–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Thompson K, Majd H, Dallabona C, Reinson K, King MS, Alston CL, et al. Recurrent de novo dominant mutations in SLC25A4 cause severe early-onset mitochondrial disease and loss of mitochondrial DNA copy number. Am J Hum Genet. 2016;99(4):860–76.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Palmieri L, Alberio S, Pisano I, Lodi T, Meznaric-Petrusa M, Zidar J, et al. Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy. Hum Mol Genet. 2005;14(20):3079–88.PubMedCrossRefGoogle Scholar
  30. 30.
    Echaniz-Laguna A, Chassagne M, Ceresuela J, Rouvet I, Padet S, Acquaviva C, et al. Complete loss of expression of the ANT1 gene causing cardiomyopathy and myopathy. J Med Genet. 2012;49(2):146–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003;278(10):7743–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci U S A. 2004;101(45):15927–32.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Elachouri G, Vidoni S, Zanna C, Pattyn A, Boukhaddaoui H, Gaget K, et al. OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res. 2011;21(1):12–20.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26(2):207–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133(Pt 3):771–86.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Schaaf CP, Blazo M, Lewis RA, Tonini RE, Takei H, Wang J, et al. Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations. Mol Genet Metab. 2011;103(4):383–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Pyle A, Ramesh V, Bartsakoulia M, Boczonadi V, Gomez-Duran A, Herczegfalvi A, et al. Behr’s syndrome is typically associated with disturbed mitochondrial translation and mutations in the C12orf65 gene. J Neuromuscul Dis. 2014;1(1):55–63.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Spiegel R, Saada A, Flannery PJ, Burte F, Soiferman D, Khayat M, et al. Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation. J Med Genet. 2016;53(2):127–31.PubMedCrossRefGoogle Scholar
  39. 39.
    Ostergaard E, Christensen E, Kristensen E, Mogensen B, Duno M, Shoubridge EA, et al. Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. Am J Hum Genet. 2007;81(2):383–7.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Kowluru A, Tannous M, Chen HQ. Localization and characterization of the mitochondrial isoform of the nucleoside diphosphate kinase in the pancreatic beta cell: evidence for its complexation with mitochondrial succinyl-CoA synthetase. Arch Biochem Biophys. 2002;398(2):160–9.PubMedCrossRefGoogle Scholar
  41. 41.
    James M, Man NT, Edwards YH, Morris GE. The molecular basis for cross-reaction of an anti-dystrophin antibody with alpha-actinin. Biochim Biophys Acta. 1997;1360(2):169–76.PubMedCrossRefGoogle Scholar
  42. 42.
    Ostergaard E, Schwartz M, Batbayli M, Christensen E, Hjalmarson O, Kollberg G, et al. A novel missense mutation in SUCLG1 associated with mitochondrial DNA depletion, encephalomyopathic form, with methylmalonic aciduria. Eur J Pediatr. 2010;169(2):201–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Rouzier C, Le Guedard-Mereuze S, Fragaki K, Serre V, Miro J, Tuffery-Giraud S, et al. The severity of phenotype linked to SUCLG1 mutations could be correlated with residual amount of SUCLG1 protein. J Med Genet. 2010;47(10):670–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Carrozzo R, Verrigni D, Rasmussen M, de Coo R, Amartino H, Bianchi M, et al. Succinate-CoA ligase deficiency due to mutations in SUCLA2 and SUCLG1: phenotype and genotype correlations in 71 patients. J Inherit Metab Dis. 2016;39(2):243–52.PubMedCrossRefGoogle Scholar
  45. 45.
    Donti TR, Masand R, Scott DA, Craigen WJ, Graham BH. Expanding the phenotypic spectrum of Succinyl-CoA ligase deficiency through functional validation of a new SUCLG1 variant. Mol Genet Metab. 2016;119(1–2):68–74.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Lambeth DO, Tews KN, Adkins S, Frohlich D, Milavetz BI. Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues. J Biol Chem. 2004;279(35):36621–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Ostergaard E, Hansen FJ, Sorensen N, Duno M, Vissing J, Larsen PL, et al. Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. Brain. 2007;130(Pt 3):853–61.PubMedCrossRefGoogle Scholar
  48. 48.
    Carrozzo R, Dionisi-Vici C, Steuerwald U, Lucioli S, Deodato F, Di Giandomenico S, et al. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain. 2007;130(Pt 3):862–74.PubMedCrossRefGoogle Scholar
  49. 49.
    Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007;39(6):776–80.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Foskolou IP, Jorgensen C, Leszczynska KB, Olcina MM, Tarhonskaya H, Haisma B, et al. Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication. Mol Cell. 2017;66(2):206–220.e9.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Bornstein B, Area E, Flanigan KM, Ganesh J, Jayakar P, Swoboda KJ, et al. Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. Neuromuscul Disord. 2008;18(6):453–9.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Kollberg G, Darin N, Benan K, Moslemi AR, Lindal S, Tulinius M, et al. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord. 2009;19(2):147–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Tyynismaa H, Ylikallio E, Patel M, Molnar MJ, Haller RG, Suomalainen A. A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet. 2009;85(2):290–5.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Kropach N, Shkalim-Zemer V, Orenstein N, Scheuerman O, Straussberg R. Novel RRM2B mutation and severe mitochondrial DNA depletion: report of 2 cases and review of the literature. Neuropediatrics. 2017;48(6):456–62.PubMedCrossRefGoogle Scholar
  55. 55.
    Pitceathly RD, Fassone E, Taanman JW, Sadowski M, Fratter C, Mudanohwo EE, et al. Kearns-Sayre syndrome caused by defective R1/p53R2 assembly. J Med Genet. 2011;48(9):610–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Fratter C, Raman P, Alston CL, Blakely EL, Craig K, Smith C, et al. RRM2B mutations are frequent in familial PEO with multiple mtDNA deletions. Neurology. 2011;76(23):2032–4.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Pitceathly RD, Smith C, Fratter C, Alston CL, He L, Craig K, et al. Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics. Brain. 2012;135(Pt 11):3392–403.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Shaibani A, Shchelochkov OA, Zhang S, Katsonis P, Lichtarge O, Wong LJ, et al. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol. 2009;66(8):1028–32.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Bonnen PE, Yarham JW, Besse A, Wu P, Faqeih EA, Al-Asmari AM, et al. Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. Am J Hum Genet. 2013;93(3):471–81.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Gai X, Ghezzi D, Johnson MA, Biagosch CA, Shamseldin HE, Haack TB, et al. Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. Am J Hum Genet. 2013;93(3):482–95.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Huemer M, Karall D, Schossig A, Abdenur JE, Al Jasmi F, Biagosch C, et al. Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to FBXL4 mutations. J Inherit Metab Dis. 2015;38(5):905–14.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    El-Hattab AW, Dai H, Almannai M, Wang J, Faqeih EA, Al Asmari A, et al. Molecular and clinical spectra of FBXL4 deficiency. Hum Mutat. 2017;38(12):1649–59.PubMedCrossRefGoogle Scholar
  63. 63.
    Ebrahimi-Fakhari D, Seitz A, Kolker S, Hoffmann GF. Recurrent stroke-like episodes in FBXL4-associated early-onset mitochondrial encephalomyopathy. Pediatr Neurol. 2015;53(6):549–50.PubMedCrossRefGoogle Scholar
  64. 64.
    Boczonadi V, King MS, Smith AC, Olahova M, Bansagi B, Roos A, et al. Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. Genet Med. 2018;20(10):1224–35.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Johansson M, Karlsson A. Cloning and expression of human deoxyguanosine kinase cDNA. Proc Natl Acad Sci U S A. 1996;93(14):7258–62.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet. 2001;29(3):337–41.PubMedCrossRefGoogle Scholar
  67. 67.
    Taanman JW, Kateeb I, Muntau AC, Jaksch M, Cohen N, Mandel H. A novel mutation in the deoxyguanosine kinase gene causing depletion of mitochondrial DNA. Ann Neurol. 2002;52(2):237–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Dimmock DP, Zhang Q, Dionisi-Vici C, Carrozzo R, Shieh J, Tang LY, et al. Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase. Hum Mutat. 2008;29(2):330–1.PubMedCrossRefGoogle Scholar
  69. 69.
    Ronchi D, Garone C, Bordoni A, Gutierrez Rios P, Calvo SE, Ripolone M, et al. Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions. Brain. 2012;135(Pt 11):3404–15.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Ducluzeau PH, Lachaux A, Bouvier R, Duborjal H, Stepien G, Bozon D, et al. Progressive reversion of clinical and molecular phenotype in a child with liver mitochondrial DNA depletion. J Hepatol. 2002;36(5):698–703.PubMedCrossRefGoogle Scholar
  71. 71.
    Mousson de Camaret B, Taanman JW, Padet S, Chassagne M, Mayencon M, Clerc-Renaud P, et al. Kinetic properties of mutant deoxyguanosine kinase in a case of reversible hepatic mtDNA depletion. Biochem J. 2007;402(2):377–85.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Vilarinho S, Sari S, Yilmaz G, Stiegler AL, Boggon TJ, Jain D, et al. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology. 2016;63(6):1977–86.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Lee NC, Dimmock D, Hwu WL, Tang LY, Huang WC, Chinault AC, et al. Simultaneous detection of mitochondrial DNA depletion and single-exon deletion in the deoxyguanosine gene using array-based comparative genomic hybridisation. Arch Dis Child. 2009;94(1):55–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Al-Hussaini A, Faqeih E, El-Hattab AW, Alfadhel M, Asery A, Alsaleem B, et al. Clinical and molecular characteristics of mitochondrial DNA depletion syndrome associated with neonatal cholestasis and liver failure. J Pediatr. 2014;164(3):553–9.e1-2.PubMedCrossRefGoogle Scholar
  75. 75.
    Grabhorn E, Tsiakas K, Herden U, Fischer L, Freisinger P, Marquardt T, et al. Long-term outcomes after liver transplantation for deoxyguanosine kinase deficiency: a single-center experience and a review of the literature. Liver Transpl. 2014;20(4):464–72.PubMedCrossRefGoogle Scholar
  76. 76.
    Dallabona C, Marsano RM, Arzuffi P, Ghezzi D, Mancini P, Zeviani M, et al. Sym1, the yeast ortholog of the MPV17 human disease protein, is a stress-induced bioenergetic and morphogenetic mitochondrial modulator. Hum Mol Genet. 2010;19(6):1098–107.PubMedCrossRefGoogle Scholar
  77. 77.
    Lollgen S, Weiher H. The role of the Mpv17 protein mutations of which cause mitochondrial DNA depletion syndrome (MDDS): lessons from homologs in different species. Biol Chem. 2015;396(1):13–25.PubMedCrossRefGoogle Scholar
  78. 78.
    Antonenkov VD, Isomursu A, Mennerich D, Vapola MH, Weiher H, Kietzmann T, et al. The human mitochondrial DNA depletion syndrome gene MPV17 encodes a non-selective channel that modulates membrane potential. J Biol Chem. 2015;290(22):13840–61.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Dalla Rosa I, Camara Y, Durigon R, Moss CF, Vidoni S, Akman G, et al. MPV17 loss causes deoxynucleotide insufficiency and slow DNA replication in mitochondria. PLoS Genet. 2016;12(1):e1005779.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Moss CF, Dalla Rosa I, Hunt LE, Yasukawa T, Young R, Jones AWE, et al. Aberrant ribonucleotide incorporation and multiple deletions in mitochondrial DNA of the murine MPV17 disease model. Nucleic Acids Res. 2017;45(22):12808–15.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F, D’Adamo P, Calvo S, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet. 2006;38(5):570–5.PubMedCrossRefGoogle Scholar
  82. 82.
    Karadimas CL, Vu TH, Holve SA, Chronopoulou P, Quinzii C, Johnsen SD, et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am J Hum Genet. 2006;79(3):544–8.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Uusimaa J, Evans J, Smith C, Butterworth A, Craig K, Ashley N, et al. Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene. Eur J Hum Genet. 2014;22(2):184–91.PubMedCrossRefGoogle Scholar
  84. 84.
    Spinazzola A, Santer R, Akman OH, Tsiakas K, Schaefer H, Ding X, et al. Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations. Arch Neurol. 2008;65(8):1108–13.PubMedCrossRefGoogle Scholar
  85. 85.
    Navarro-Sastre A, Martin-Hernandez E, Campos Y, Quintana E, Medina E, de Las Heras RS, et al. Lethal hepatopathy and leukodystrophy caused by a novel mutation in MPV17 gene: description of an alternative MPV17 spliced form. Mol Genet Metab. 2008;94(2):234–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Kaji S, Murayama K, Nagata I, Nagasaka H, Takayanagi M, Ohtake A, et al. Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. Mol Genet Metab. 2009;97(4):292–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Merkle AN, Nascene DR, McKinney AM. MR imaging findings in the reticular formation in siblings with MPV17-related mitochondrial depletion syndrome. AJNR Am J Neuroradiol. 2012;33(3):E34–5.PubMedCrossRefGoogle Scholar
  88. 88.
    El-Hattab AW, Li FY, Schmitt E, Zhang S, Craigen WJ, Wong LJ. MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: new patients and novel mutations. Mol Genet Metab. 2010;99(3):300–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Bertazzoni U, Scovassi AI, Brun GM. Chick-embryo DNA polymerase gamma. Identity of gamma-polymerases purified from nuclei and mitochondria. Eur J Biochem. 1977;81(2):237–48.PubMedCrossRefGoogle Scholar
  90. 90.
    Lestienne P. Evidence for a direct role of the DNA polymerase gamma in the replication of the human mitochondrial DNA in vitro. Biochem Biophys Res Commun. 1987;146(3):1146–53.PubMedCrossRefGoogle Scholar
  91. 91.
    Carrodeguas JA, Theis K, Bogenhagen DF, Kisker C. Crystal structure and deletion analysis show that the accessory subunit of mammalian DNA polymerase gamma, Pol gamma B, functions as a homodimer. Mol Cell. 2001;7(1):43–54.PubMedCrossRefGoogle Scholar
  92. 92.
    Longley MJ, Clark S, Yu Wai Man C, Hudson G, Durham SE, Taylor RW, et al. Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am J Hum Genet. 2006;78(6):1026–34.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Chinnery PF, Zeviani M. 155th ENMC workshop: polymerase gamma and disorders of mitochondrial DNA synthesis, 21-23 September 2007, Naarden, The Netherlands. Neuromuscul Disord. 2008;18(3):259–67.PubMedCrossRefGoogle Scholar
  94. 94.
    Hikmat O, Tzoulis C, Chong WK, Chentouf L, Klingenberg C, Fratter C, et al. The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. Genet Med. 2017;19(11):1217–25.PubMedCrossRefGoogle Scholar
  95. 95.
    Anagnostou ME, Ng YS, Taylor RW, McFarland R. Epilepsy due to mutations in the mitochondrial polymerase gamma (POLG) gene: a clinical and molecular genetic review. Epilepsia. 2016;57(10):1531–45.PubMedCrossRefGoogle Scholar
  96. 96.
    Neeve VC, Samuels DC, Bindoff LA, van den Bosch B, Van Goethem G, Smeets H, et al. What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr? Brain. 2012;135(Pt 12):3614–26.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Nikkanen J, Landoni JC, Balboa D, Haugas M, Partanen J, Paetau A, et al. A complex genomic locus drives mtDNA replicase POLG expression to its disease-related nervous system regions. EMBO Mol Med. 2018;10(1):13–21.PubMedCrossRefGoogle Scholar
  98. 98.
    Alpers BJ. Diffuse progressive degeneration of the gray matter of the cerebrum. Arch Neurol Psych. 1931;25(3):469–505.CrossRefGoogle Scholar
  99. 99.
    Naviaux RK, Nguyen KV. POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Ann Neurol. 2004;55(5):706–12.PubMedCrossRefGoogle Scholar
  100. 100.
    Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. 2001;49(3):377–83.PubMedCrossRefGoogle Scholar
  101. 101.
    Horvath R, Hudson G, Ferrari G, Futterer N, Ahola S, Lamantea E, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain. 2006;129(Pt 7):1674–84.PubMedCrossRefGoogle Scholar
  102. 102.
    Nguyen KV, Ostergaard E, Ravn SH, Balslev T, Danielsen ER, Vardag A, et al. POLG mutations in Alpers syndrome. Neurology. 2005;65(9):1493–5.PubMedCrossRefGoogle Scholar
  103. 103.
    Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993.Google Scholar
  104. 104.
    Davidzon G, Greene P, Mancuso M, Klos KJ, Ahlskog JE, Hirano M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol. 2006;59(5):859–62.PubMedCrossRefGoogle Scholar
  105. 105.
    Worle H, Kohler B, Schlote W, Winkler P, Bastanier CK. Progressive cerebral degeneration of childhood with liver disease (Alpers Huttenlocher disease) with cytochrome oxidase deficiency presenting with epilepsia partialis continua as the first clinical manifestation. Clin Neuropathol. 1998;17(2):63–8.PubMedGoogle Scholar
  106. 106.
    Naviaux RK, Nyhan WL, Barshop BA, Poulton J, Markusic D, Karpinski NC, et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers’ syndrome. Ann Neurol. 1999;45(1):54–8.PubMedCrossRefGoogle Scholar
  107. 107.
    Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain. 2006;129(Pt 7):1685–92.PubMedCrossRefGoogle Scholar
  108. 108.
    Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure. 2010;19(3):140–6.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamaki M, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet. 2005;77(3):430–41.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Engelsen BA, Tzoulis C, Karlsen B, Lillebo A, Laegreid LM, Aasly J, et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain. 2008;131(Pt 3):818–28.PubMedCrossRefGoogle Scholar
  111. 111.
    Smith JK, Mah JK, Castillo M. Brain MR imaging findings in two patients with Alpers’ syndrome. Clin Imaging. 1996;20(4):235–7.PubMedCrossRefGoogle Scholar
  112. 112.
    Nguyen KV, Sharief FS, Chan SS, Copeland WC, Naviaux RK. Molecular diagnosis of Alpers syndrome. J Hepatol. 2006;45(1):108–16.PubMedCrossRefGoogle Scholar
  113. 113.
    Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. Pediatr Neurol. 2013;48(3):167–78.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Ferrari G, Lamantea E, Donati A, Filosto M, Briem E, Carrara F, et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gamma A. Brain. 2005;128(Pt 4):723–31.PubMedCrossRefGoogle Scholar
  115. 115.
    Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat. 2008;29(9):E150–72.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Van Goethem G, Luoma P, Rantamaki M, Al Memar A, Kaakkola S, Hackman P, et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology. 2004;63(7):1251–7.PubMedCrossRefGoogle Scholar
  117. 117.
    Winterthun S, Ferrari G, He L, Taylor RW, Zeviani M, Turnbull DM, et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology. 2005;64(7):1204–8.PubMedCrossRefGoogle Scholar
  118. 118.
    Fadic R, Russell JA, Vedanarayanan VV, Lehar M, Kuncl RW, Johns DR. Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. Neurology. 1997;49(1):239–45.PubMedCrossRefGoogle Scholar
  119. 119.
    Van Goethem G, Martin JJ, Dermaut B, Lofgren A, Wibail A, Ververken D, et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord. 2003;13(2):133–42.PubMedCrossRefGoogle Scholar
  120. 120.
    Mancuso M, Filosto M, Bellan M, Liguori R, Montagna P, Baruzzi A, et al. POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness. Neurology. 2004;62(2):316–8.PubMedCrossRefGoogle Scholar
  121. 121.
    Lamantea E, Tiranti V, Bordoni A, Toscano A, Bono F, Servidei S, et al. Mutations of mitochondrial DNA polymerase gamma A are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol. 2002;52(2):211–9.PubMedCrossRefGoogle Scholar
  122. 122.
    Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet. 2001;28(3):211–2.PubMedCrossRefGoogle Scholar
  123. 123.
    Van Goethem G, Mercelis R, Lofgren A, Seneca S, Ceuterick C, Martin JJ, et al. Patient homozygous for a recessive POLG mutation presents with features of MERRF. Neurology. 2003;61(12):1811–3.PubMedCrossRefGoogle Scholar
  124. 124.
    Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet. 2004;364(9437):875–82.PubMedCrossRefGoogle Scholar
  125. 125.
    Tang S, Dimberg EL, Milone M, Wong LJ. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations. J Neurol. 2012;259(5):862–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Deschauer M, Tennant S, Rokicka A, He L, Kraya T, Turnbull DM, et al. MELAS associated with mutations in the POLG1 gene. Neurology. 2007;68(20):1741–2.PubMedCrossRefGoogle Scholar
  127. 127.
    Pagnamenta AT, Taanman JW, Wilson CJ, Anderson NE, Marotta R, Duncan AJ, et al. Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma. Hum Reprod. 2006;21(10):2467–73.PubMedCrossRefGoogle Scholar
  128. 128.
    McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child. 2008;93(2):151–3.PubMedCrossRefGoogle Scholar
  129. 129.
    Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 2010;52(5):1791–6.PubMedCrossRefGoogle Scholar
  130. 130.
    Sitarz KS, Elliott HR, Karaman BS, Relton C, Chinnery PF, Horvath R. Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts. Mol Genet Metab. 2014;112(1):57–63.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, Tariq M, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet. 2001;28(3):223–31.PubMedCrossRefGoogle Scholar
  132. 132.
    Van Hove JL, Cunningham V, Rice C, Ringel SP, Zhang Q, Chou PC, et al. Finding twinkle in the eyes of a 71-year-old lady: a case report and review of the genotypic and phenotypic spectrum of TWINKLE-related dominant disease. Am J Med Genet A. 2009;149A(5):861–7.PubMedCrossRefGoogle Scholar
  133. 133.
    Nikali K, Suomalainen A, Saharinen J, Kuokkanen M, Spelbrink JN, Lonnqvist T, et al. Infantile onset spinocerebellar ataxia is caused by recessive mutations in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet. 2005;14(20):2981–90.PubMedCrossRefGoogle Scholar
  134. 134.
    Morino H, Pierce SB, Matsuda Y, Walsh T, Ohsawa R, Newby M, et al. Mutations in Twinkle primase-helicase cause Perrault syndrome with neurologic features. Neurology. 2014;83(22):2054–61.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Sarzi E, Goffart S, Serre V, Chretien D, Slama A, Munnich A, et al. Twinkle helicase (PEO1) gene mutation causes mitochondrial DNA depletion. Ann Neurol. 2007;62(6):579–87.PubMedCrossRefGoogle Scholar
  136. 136.
    Goh V, Helbling D, Biank V, Jarzembowski J, Dimmock D. Next-generation sequencing facilitates the diagnosis in a child with twinkle mutations causing cholestatic liver failure. J Pediatr Gastroenterol Nutr. 2012;54(2):291–4.PubMedCrossRefGoogle Scholar
  137. 137.
    Hakonen AH, Isohanni P, Paetau A, Herva R, Suomalainen A, Lonnqvist T. Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion. Brain. 2007;130(Pt 11):3032–40.PubMedCrossRefGoogle Scholar
  138. 138.
    Prasad C, Melancon SB, Rupar CA, Prasad AN, Nunez LD, Rosenblatt DS, et al. Exome sequencing reveals a homozygous mutation in TWINKLE as the cause of multisystemic failure including renal tubulopathy in three siblings. Mol Genet Metab. 2013;108(3):190–4.PubMedCrossRefGoogle Scholar
  139. 139.
    Lonnqvist T, Paetau A, Valanne L, Pihko H. Recessive twinkle mutations cause severe epileptic encephalopathy. Brain. 2009;132(Pt 6):1553–62.PubMedCrossRefGoogle Scholar
  140. 140.
    Hakonen AH, Goffart S, Marjavaara S, Paetau A, Cooper H, Mattila K, et al. Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion. Hum Mol Genet. 2008;17(23):3822–35.PubMedCrossRefGoogle Scholar
  141. 141.
    Oldak M, Ozieblo D, Pollak A, Stepniak I, Lazniewski M, Lechowicz U, et al. Novel neuro-audiological findings and further evidence for TWNK involvement in Perrault syndrome. J Transl Med. 2017;15(1):25.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Van Goethem G, Lofgren A, Dermaut B, Ceuterick C, Martin JJ, Van Broeckhoven C. Digenic progressive external ophthalmoplegia in a sporadic patient: recessive mutations in POLG and C10orf2/Twinkle. Hum Mutat. 2003;22(2):175–6.PubMedCrossRefGoogle Scholar
  143. 143.
    Baloh RH, Salavaggione E, Milbrandt J, Pestronk A. Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle. Arch Neurol. 2007;64(7):998–1000.PubMedCrossRefGoogle Scholar
  144. 144.
    Echaniz-Laguna A, Chanson JB, Wilhelm JM, Sellal F, Mayencon M, Mohr M, et al. A novel variation in the Twinkle linker region causing late-onset dementia. Neurogenetics. 2010;11(1):21–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Fratter C, Gorman GS, Stewart JD, Buddles M, Smith C, Evans J, et al. The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology. 2010;74(20):1619–26.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Kiferle L, Orsucci D, Mancuso M, Lo Gerfo A, Petrozzi L, Siciliano G, et al. Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: a case report and an update on the state of art. Neurosci Lett. 2013;556:1–4.PubMedCrossRefGoogle Scholar
  147. 147.
    Parisi MA, Clayton DA. Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science. 1991;252(5008):965–9.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Stiles AR, Simon MT, Stover A, Eftekharian S, Khanlou N, Wang HL, et al. Mutations in TFAM, encoding mitochondrial transcription factor A, cause neonatal liver failure associated with mtDNA depletion. Mol Genet Metab. 2016;119(1–2):91–9.PubMedCrossRefGoogle Scholar
  149. 149.
    Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 1999;283(5402):689–92.CrossRefGoogle Scholar
  150. 150.
    Van Goethem G, Schwartz M, Lofgren A, Dermaut B, Van Broeckhoven C, Vissing J. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet. 2003;11(7):547–9.PubMedCrossRefGoogle Scholar
  151. 151.
    Verny C, Amati-Bonneau P, Letournel F, Person B, Dib N, Malinge MC, et al. Mitochondrial DNA A3243G mutation involved in familial diabetes, chronic intestinal pseudo-obstruction and recurrent pancreatitis. Diabetes Metab. 2008;34(6 Pt 1):620–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Sekino Y, Inamori M, Yamada E, Ohkubo H, Sakai E, Higurashi T, et al. Characteristics of intestinal pseudo-obstruction in patients with mitochondrial diseases. World J Gastroenterol. 2012;18(33):4557–62.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Ng YS, Feeney C, Schaefer AM, Holmes CE, Hynd P, Alston CL, et al. Pseudo-obstruction, stroke, and mitochondrial dysfunction: a lethal combination. Ann Neurol. 2016;80(5):686–92.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, et al. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun. 1992;184(3):1311–6.PubMedCrossRefGoogle Scholar
  155. 155.
    Asai K, Nakanishi K, Isobe I, Eksioglu YZ, Hirano A, Hama K, et al. Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor. J Biol Chem. 1992;267(28):20311–6.PubMedGoogle Scholar
  156. 156.
    Matsukawa K, Moriyama A, Kawai Y, Asai K, Kato T. Tissue distribution of human gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced expression. Biochim Biophys Acta. 1996;1314(1–2):71–82.PubMedCrossRefGoogle Scholar
  157. 157.
    Bardosi A, Creutzfeldt W, DiMauro S, Felgenhauer K, Friede RL, Goebel HH, et al. Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase. A new mitochondrial multisystem disorder. Acta Neuropathol. 1987;74(3):248–58.CrossRefGoogle Scholar
  158. 158.
    Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahn CD, et al. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol. 2000;47(6):792–800.PubMedCrossRefGoogle Scholar
  159. 159.
    Giordano C, Sebastiani M, De Giorgio R, Travaglini C, Tancredi A, Valentino ML, et al. Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol. 2008;173(4):1120–8.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Hirano M, Nishigaki Y, Marti R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. Neurologist. 2004;10(1):8–17.CrossRefGoogle Scholar
  161. 161.
    Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2011;134(Pt 11):3326–32.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Kalkan IH, Tayfur O, Oztas E, Beyazit Y, Yildiz H, Tunc B. A novel finding in MNGIE (mitochondrial neurogastrointestinal encephalomyopathy): hypergonadotropic hypogonadism. Hormones (Athens). 2012;11(3):377–9.CrossRefGoogle Scholar
  163. 163.
    Marti R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M. Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem. 2004;50(1):120–4.PubMedCrossRefGoogle Scholar
  164. 164.
    Vissing J, Ravn K, Danielsen ER, Duno M, Wibrand F, Wevers RA, et al. Multiple mtDNA deletions with features of MNGIE. Neurology. 2002;59(6):926–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Perez-Atayde AR, Fox V, Teitelbaum JE, Anthony DA, Fadic R, Kalsner L, et al. Mitochondrial neurogastrointestinal encephalomyopathy: diagnosis by rectal biopsy. Am J Surg Pathol. 1998;22(9):1141–7.PubMedCrossRefGoogle Scholar
  166. 166.
    Teitelbaum JE, Berde CB, Nurko S, Buonomo C, Perez-Atayde AR, Fox VL. Diagnosis and management of MNGIE syndrome in children: case report and review of the literature. J Pediatr Gastroenterol Nutr. 2002;35(3):377–83.PubMedCrossRefGoogle Scholar
  167. 167.
    Saada A. Mitochondrial deoxyribonucleotide pools in deoxyguanosine kinase deficiency. Mol Genet Metab. 2008;95(3):169–73.PubMedCrossRefGoogle Scholar
  168. 168.
    Bulst S, Abicht A, Holinski-Feder E, Muller-Ziermann S, Koehler U, Thirion C, et al. In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. Hum Mol Genet. 2009;18(9):1590–9.PubMedCrossRefGoogle Scholar
  169. 169.
    Bulst S, Holinski-Feder E, Payne B, Abicht A, Krause S, Lochmuller H, et al. In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion. Mol Genet Metab. 2012;107(1–2):95–103.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Spinazzola A, Marti R, Nishino I, Andreu AL, Naini A, Tadesse S, et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem. 2002;277(6):4128–33.CrossRefGoogle Scholar
  171. 171.
    Yavuz H, Ozel A, Christensen M, Christensen E, Schwartz M, Elmaci M, et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol. 2007;64(3):435–8.CrossRefGoogle Scholar
  172. 172.
    Hirano M, Marti R, Casali C, Tadesse S, Uldrick T, Fine B, et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology. 2006;67(8):1458–60.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Halter J, Schupbach W, Casali C, Elhasid R, Fay K, Hammans S, et al. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant. 2011;46(3):330–7.PubMedCrossRefGoogle Scholar
  174. 174.
    Sicurelli F, Carluccio MA, Toraldo F, Tozzi M, Bucalossi A, Lenoci M, et al. Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-up. J Neurol. 2012;259(9):1985–7.PubMedCrossRefGoogle Scholar
  175. 175.
    Roeben B, Marquetand J, Bender B, Billing H, Haack TB, Sanchez-Albisua I, et al. Hemodialysis in MNGIE transiently reduces serum and urine levels of thymidine and deoxyuridine, but not CSF levels and neurological function. Orphanet J Rare Dis. 2017;12(1):135.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Di Giorgio A, Sonzogni A, Picciche A, Alessio G, Bonanomi E, Colledan M, et al. Successful management of acute liver failure in Italian children: a 16-year experience at a referral centre for paediatric liver transplantation. Dig Liver Dis. 2017;49(10):1139–45.PubMedCrossRefGoogle Scholar
  177. 177.
    El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics. 2013;10(2):186–98.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    El-Hattab AW, Craigen WJ, Scaglia F. Mitochondrial DNA maintenance defects. Biochim Biophys Acta. 2017;1863(6):1539–55.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sumit Parikh
    • 1
  • Rita Horvath
    • 2
  1. 1.Mitochondrial Medicine Center, Neurological InstituteCleveland ClinicClevelandUSA
  2. 2.Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic MedicineNewcastle UniversityNewcastle Upon TyneUK

Personalised recommendations